TORONTO, ON / ACCESSWIRE / Might 4, 2021 / Ripple Therapeutics Company (“Ripple”) a scientific stage, ophthalmology-focused developer of novel prescription drugs, is happy to announce the appointment of Jonathan Talamo, M.D., to the Board of Administrators. Dr. Talamo is internationally often called an ophthalmologist, innovator and advisor to business with greater than 25 years of expertise in healthcare.

Dr. Talamo is the previous Chief Medical Officer and Worldwide VP of Scientific and Medical Affairs at Johnson and Johnson Imaginative and prescient. Previous to that, he served because the Chief Medical Officer at Ocular Therapeutix, an ophthalmic drug supply firm, the place he oversaw scientific improvement packages in a number of therapeutic areas, together with post-cataract surgical procedure irritation, dry eye, allergy, glaucoma and retinal vascular illnesses.

“As a long-time working towards Ophthalmologist who has additionally labored in business to develop extended-release ophthalmic medicines, I do know there are big unmet wants for sufferers throughout a number of illness states”, commented Dr. Talamo. “I am actually excited to work with the Ripple crew to convey first-in-class proprietary extended-release ophthalmic therapeutics to market.”

“We’re extraordinarily happy to have Dr. Talamo be a part of our Board of Administrators”, said Tom Reeves, President and CEO, Ripple Therapeutics. “He brings a singular mixture of scientific experience as a working towards ophthalmologist and business expertise with each giant and small corporations. He will probably be an awesome asset for Ripple as we glance to understand on our imaginative and prescient of offering protected and efficient therapy choices for sufferers with sight-threatening circumstances.”

About Ripple Therapeutics:

Ripple Therapeutics Company is a scientific stage privately held firm that’s targeted on enhancing ophthalmic therapeutics with controllable, sustainable drug supply. The core function of Ripple’s Epidel know-how is the flexibility to engineer medicine into supplies with zero-order launch kinetics with out using polymers or excipients. Ripple has a full product pipeline in improvement.

Media Contact:

Julie Fotheringham, V.P. Advertising and marketing, Folks & Tradition

M: 416-951-7988 E:

SOURCE: Ripple Therapeutics


View supply model on


Source link